EGX
9.20 EGP
+15.00%More than 12 months
Buy stock at the current price
March 15, 2026 at 8:40:57 PM
Medium
85.00%
15.00%
Ibnsina Pharma has demonstrated robust financial performance, with a 64.49% increase in revenue in 2024, reaching EGP 55.84 billion, and a 187.51% rise in earnings to EGP 497.80 million. The company's strategic positioning as a leading pharmaceutical distributor in Egypt, coupled with its extensive network and services, positions it well for continued growth.
The stock has shown significant growth, with a 166.67% increase over the past year and a 26.18% rise over the past month, indicating strong market confidence.
The growing demand for healthcare services in Egypt, driven by a rising population and increased healthcare awareness, creates a favorable environment for pharmaceutical distributors like Ibnsina Pharma.
Ibnsina Pharma's extensive distribution network and comprehensive service offerings, including warehousing, logistics, and marketing solutions, provide a competitive edge in the Egyptian pharmaceutical market.
Ibnsina Pharma's strong financial performance, strategic market positioning, and favorable economic conditions suggest a promising growth trajectory, making it a suitable candidate for investment.
- Robust financial growth with a 64.49% revenue increase in 2024.
- Strategic market leader in Egypt's pharmaceutical distribution.
- Favorable economic conditions supporting healthcare demand.
- Analysts recommend a 'Strong Buy' with a target price of EGP 9.20.
